Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday. Separately, Maxim Group increased their target price on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, […]
StockNews.com downgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a report issued on Friday morning. Separately, Maxim Group boosted their price target on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the company a buy rating in a report on Friday, March 31st. […]
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.